Guggenheim lowered the firm’s price target on Neurocrine (NBIX) to $155 from $163 and keeps a Buy rating on the shares. The firm, in its ...

Return on Assets (ROA): Neurocrine Biosciences's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 2.84%, the company showcases ...

Neurocrine Biosciences’ Kinect 4 open-label study (NCT02405091) found that 59.2% of patients achieved remission of tardive dyskinesia through once-daily doses of Ingrezza (valbenazine). Post-hoc ...

Neurocrine Biosciences (NASDAQ:NBIX – Free Report) had its price target reduced by UBS Group from $154.00 to $137.00 in a research report report published on Friday,Benzinga reports. They currently ...

In this article, we are going to take a look at where Neurocrine Biosciences, Inc. (NASDAQ:NBIX) stands against other best biotech stocks. Although biotech stocks had a “challenging” year in ...

Neurocrine Biosciences declared that its Board of Directors has authorized a stock buyback program on Friday, February 21st that allows the company to buyback $500.00 million in outstanding shares.

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Clearly, options traders are pricing in a big move for Neurocrine Biosciences share, but what is the fundamental picture for the company? Currently, Neurocrine Biosciences is a Zacks Rank #5 ...

UBS analyst Ashwani Verma lowered the firm’s price target on Neurocrine (NBIX) to $137 from $154 and keeps a Buy rating on the shares. The ...

SAN DIEGO, March 20, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today presented new data from the long-term, open-label KINECT® 4 study demonstrating remission of tardive ...

Neurocrine Biosciences’ Kinect 4 open-label study (NCT02405091) found that 59.2% of patients achieved remission of tardive dyskinesia through once-daily doses of Ingrezza (valbenazine).